The Scottish Medicines Consortium (SMC) has accepted BIMZELX®▼ (bimekizumab) for use by NHS Scotland as a treatment option for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy and have failed to respond to standard systemic therapies, are intolerant to, or have a contra-indication to these treatments.
The acceptance was expedited through SMC’s fast track process, which was set up in response to the Covid-19 pandemic, taking a total of 4 months and 3 days from submission to acceptance.
Bimekizumab is the first available treatment in Scotland that selectively inhibits two key inflammatory cytokines, IL-17A and IL-17F.[1,2] These cytokines aid cell to cell communication in immune responses and help drive inflammatory processes. Given their role in driving chronic tissue inflammation, targeting both cytokines is believed to help suppress inflammation in patients.
Dr Areti Makrygeorgou, Associate Specialist Dermatologist, West Ambulatory Care Hospital, Glasgow said: “Patients with psoriasis and Dermatologists in Scotland welcome the SMC’s recommendation of bimekizumab for the treatment of moderate to severe psoriasis in candidates for systemic therapy. This monoclonal antibody is a significant addition to the family of Th17 pathway inhibitors for the treatment of psoriasis with the benefit of dual inhibition of IL-17A and IL-17F. With a rapid onset of action, bimekizumab achieves high rates of clearance among treated patients with an advantageous maintenance dosing every 8 weeks.
“This high performance has been demonstrated even in patients with previous treatment experience with more than one biological agents, widening the management options for all patients with psoriasis.”
Claire Brading, Managing Director UK & Ireland, UCB said: “UCB recognises and understands the impact chronic inflammatory skin disorders, such as psoriasis, can have on people, the health care system and wider society. We are committed in continuing to drive life changing improvements in the way these conditions are managed in the UK and Ireland.”
 Scottish Medicines Consortium. Bimekizumab (Bimzelx). Available at: https://www.scottishmedicines.org.uk/medicinesadvice/bimekizumab-bimzelx-abb-smc2410/. Last accessed: November 2021.
 Glatt S et al., Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Clin Epidemiol. 2018;77:523-532